Other: Monthly assessments of functional motor abilities by a trained therapist ( DrugBank: - )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
3 | Spinal muscular atrophy | 1 |
3. Spinal muscular atrophy
Clinical trials : 217 / Drugs : 149 - (DrugBank : 33) / Drug target genes : 54 - Drug target pathways : 80
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04576494 (ClinicalTrials.gov) | December 2020 | 29/9/2020 | Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms) | Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms): a Multicenter Single-case Experimental Design in Multiple Baselines Across Subjects, Randomized, Single-blinded Evaluation | Spinal Muscular Atrophy | Other: Monthly assessments of functional motor abilities by a trained therapist;Drug: Nusinersen | CHU de Reims | NULL | Not yet recruiting | 18 Years | N/A | All | 24 | N/A | France |